Stephen Maxted Ansell, MD, PhD

  • 22202 Citations
  • 80 Scopus h-Index
1976 …2020

Research output per year

If you made any changes in Pure these will be visible here soon.

Research Output

Filter
Article
17 Scopus citations

Author reply: Flows and flaws in primary CNS lymphoma

Ansell, S. M. & Rajkumar, S. V., Aug 2010, In : Nature Reviews Clinical Oncology. 7, 8

Research output: Contribution to journalArticle

Autograft immune content and survival in non-Hodgkin's lymphoma: A post hoc analysis

Porrata, L. F., Inwards, D. J., Ansell, S. M., Micallef, I., Johnston, P. B., Villasboas Bisneto, J. J. C. . & Markovic, S. N., Jun 1 2019, In : Leukemia Research. 81, p. 1-9 9 p.

Research output: Contribution to journalArticle

Autologous hematopoietic stem cell transplantation for older patients with relapsed non-Hodgkin's lymphoma

Buadi, F. K., Micallef, I., Ansell, S. M., Porrata, L. F., Dispenzieri, A., Elliot, M. A., Gastineau, D. A., Gertz, M., Lacy, M., Litzow, M. R., Tefferi, A. & Inwards, D. J., Jun 2006, In : Bone Marrow Transplantation. 37, 11, p. 1017-1022 6 p.

Research output: Contribution to journalArticle

46 Scopus citations

Autologous stem cell transplant for immunoglobulin light chain amyloidosis: A status report

Gertz, M., Lacy, M., Dispenzieri, A., Hayman, S. R., Kumar, S. K., Dingli, D. M., Ansell, S. M., Gastineau, D. A., Inwards, D. J., Johnston, P. B., Litzow, M. R., Micallef, I., Porrata, L. F., Leung, N., Hogan, W. & Buadi, F. K., Dec 2010, In : Leukemia and Lymphoma. 51, 12, p. 2181-2187 7 p.

Research output: Contribution to journalArticle

77 Scopus citations

Autologous stem cell transplant in 716 patients with multiple myeloma: Low treatment-related mortality, feasibility of outpatient transplant, and effect of a multidisciplinary quality initiative

Gertz, M., Ansell, S. M., Dingli, D. M., Dispenzieri, A., Buadi, F. K., Elliott, M. A., Gastineau, D. A., Hayman, S. R., Hogan, W., Inwards, D. J., Johnston, P. B., Kumar, S. K., Lacy, M., Leung, N., Micallef, I., Porrata, L. F., Schafer, B. A., Wolf, R. C. & Litzow, M. R., 2008, In : Mayo Clinic Proceedings. 83, 10, p. 1131-1135 5 p.

Research output: Contribution to journalArticle

71 Scopus citations

B7-H1 (PD-L1, CD274) suppresses host immunity in T-cell lymphoproliferative disorders

Wilcox, R. A., Feldman, A. L., Wada, D. A., Yang, Z. Z., Comfere, N. I., Dong, H. M., Kwon, E. D., Novak, A. J., Markovic, S. N., Pittelkow, M. R., Witzig, T. E. & Ansell, S. M., 2009, In : Blood. 114, 10, p. 2149-2158 10 p.

Research output: Contribution to journalArticle

134 Scopus citations

B-cell activating factor-receptor specific activation of tumor necrosis factor receptor associated factor 6 and the phosphatidyl inositol 3-kinase pathway in lymphoma B cells

Secreto, F., Manske, M., Price-Troska, T., Ziesmer, S., Hodge, L. S., Ansell, S. M., Cerhan, J. R. & Novak, A. J., 2014, In : Leukemia and Lymphoma. 55, 8, p. 1884-1892 9 p.

Research output: Contribution to journalArticle

5 Scopus citations

Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenström macroglobulinemia

Paludo, J., Abeykoon, J. P., Shreders, A., Ansell, S. M., Kumar, S. K., Ailawadhi, S., King, R., Koehler, A. B., Reeder, C. B., Buadi, F. K., Dispenzieri, A., Lacy, M., Dingli, D. M., Witzig, T. E., Go, R. S., Gonsalves, W., Kourelis, T., Warsame, R., Leung, N., Habermann, T. M. & 6 others, Hayman, S., Lin, Y., Kyle, R. A., Rajkumar, S. V., Gertz, M. & Kapoor, P., Apr 3 2018, (Accepted/In press) In : Annals of Hematology. p. 1-9 9 p.

Research output: Contribution to journalArticle

13 Scopus citations

Beyond targeting malignant B cells

Ansell, S. M., Jul 2012, In : The Lancet Oncology. 13, 7, p. 657-658 2 p.

Research output: Contribution to journalArticle

Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin's lymphoma

Martin, W. G., Ristow, K. M., Habermann, T. M., Colgan, J. P., Witzig, T. E. & Ansell, S. M., 2005, In : Journal of Clinical Oncology. 23, 30, p. 7614-7620 7 p.

Research output: Contribution to journalArticle

192 Scopus citations

Bleomycin use in the treatment of Hodgkin lymphoma (HL): toxicity and outcomes in the modern era

Taparra, K., Liu, H., Polley, M. Y., Ristow, K., Habermann, T. M. & Ansell, S. M., Jan 1 2019, (Accepted/In press) In : Leukemia and Lymphoma.

Research output: Contribution to journalArticle

B-lymphocyte stimulator (BLyS) stimulates immunoglobulin production and malignant B-cell growth in Waldenström macroglobulinemia

Elsawa, S. F., Novak, A. J., Grote, D. M., Ziesmer, S. C., Witzig, T. E., Kyle, R. A., Dillon, S. R., Harder, B., Gross, J. A. & Ansell, S. M., Apr 1 2006, In : Blood. 107, 7, p. 2882-2888 7 p.

Research output: Contribution to journalArticle

76 Scopus citations
68 Scopus citations

Bowel perforation in intestinal lymphoma: Incidence and clinical features

Vaidya, R., Habermann, T. M., Donohue, J. H., Ristow, K. M., Maurer, M. J., Macon, W. R., Colgan, J. P., Inwards, D. J., Ansell, S. M., Porrata, L. F., Micallef, I., Johnston, P. B., Markovic, S. N., Thompson, C. A., Nowakowski, G. S. & Witzig Dr., T. E., Sep 2013, In : Annals of Oncology. 24, 9, p. 2439-2443 5 p., mdt188.

Research output: Contribution to journalArticle

48 Scopus citations

Brentuximab vedotin: Delivering an antimitotic drug to activated lymphoma cells

Ansell, S. M., Jan 2011, In : Expert Opinion on Investigational Drugs. 20, 1, p. 99-105 7 p.

Research output: Contribution to journalArticle

26 Scopus citations

Brentuximab vedotin

Ansell, S. M., Nov 20 2014, In : Blood. 124, 22, p. 3197-3200 4 p.

Research output: Contribution to journalArticle

52 Scopus citations

Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: A phase 1, open-label, dose-escalation study

Younes, A., Connors, J. M., Park, S. I., Fanale, M., O'Meara, M. M., Hunder, N. N., Huebner, D. & Ansell, S. M., Dec 2013, In : The Lancet Oncology. 14, 13, p. 1348-1356 9 p.

Research output: Contribution to journalArticle

185 Scopus citations

Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma

LaCasce, A. S., Gregory Bociek, R., Sawas, A., Caimi, P., Agura, E., Matous, J., Ansell, S. M., Crosswell, H. E., Islas-Ohlmayer, M., Behler, C., Cheung, E., Forero-Torres, A., Vose, J., O’Connor, O. A., Josephson, N., Wang, Y. & Advani, R., Jul 5 2018, In : Blood. 132, 1, p. 40-48 9 p.

Research output: Contribution to journalArticle

39 Scopus citations

Brentuximab Vedotin plus Chemotherapy in North American Subjects with Newly Diagnosed Stage III or IV Hodgkin Lymphoma

Ramchandren, R., Advani, R. H., Ansell, S. M., Bartlett, N. L., Chen, R., Connors, J. M., Feldman, T., Forero-Torres, A., Friedberg, J. W., Gopal, A. K., Gordon, L. I., Kuruvilla, J., Savage, K. J., Younes, A., Engley, G., Manley, T. J., Fenton, K. & Straus, D. J., Jan 1 2019, In : Clinical Cancer Research. 25, 6, p. 1718-1726 9 p.

Research output: Contribution to journalArticle

Open Access
11 Scopus citations

Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin's lymphoma

Connors, J. M., Jurczak, W., Straus, D. J., Ansell, S. M., Kim, W. S., Gallamini, A., Younes, A., Alekseev, S., Illés, A., Picardi, M., Lech-Maranda, E., Oki, Y., Feldman, T., Smolewski, P., Savage, K. J., Bartlett, N. L., Walewski, J., Chen, R., Ramchandren, R., Zinzani, P. L. & 9 others, Cunningham, D., Rosta, A., Josephson, N. C., Song, E., Sachs, J., Liu, R., Jolin, H. A., Huebner, D. & Radford, J., Jan 25 2018, In : New England Journal of Medicine. 378, 4, p. 331-344 14 p.

Research output: Contribution to journalArticle

163 Scopus citations

Cause of death in follicular lymphoma in the first decade of the rituximab era: A pooled analysis of French and US cohorts

Sarkozy, C., Maurer, M. J., Link, B. K., Ghesquieres, H., Nicolas, E., Thompson, C. A., Traverse-Glehen, A., Feldman, A. L., Allmer, C., Slager, S. L., Ansell, S. M., Habermann, T. M., Bachy, E., Cerhan, J. R. & Salles, G., Jan 10 2019, In : Journal of Clinical Oncology. 37, 2, p. 144-152 9 p.

Research output: Contribution to journalArticle

14 Scopus citations
11 Scopus citations

CD4+CD25+FOXP3+ malignant T cells in Sézary syndrome are not necessarily functional regulatory T cells

Wada, D. A., Pittelkow, M. R., Comfere, N. I., Gibson, L. E., Ansell, S. M. & Wilcox, R. A., Sep 2013, In : Journal of the American Academy of Dermatology. 69, 3, p. 485-489 5 p.

Research output: Contribution to journalArticle

6 Scopus citations
116 Scopus citations

CD40 pathway activation status predicts response to CD40 therapy in diffuse large B cell lymphoma

Burington, B., Yue, P., Shi, X., Advani, R., Lau, J. T., Tan, J., Stinson, S., Stinson, J., Januario, T., De Vos, S., Ansell, S. M., Forero-Torres, A., Fedorowicz, G., Yang, T. T. C., Elkins, K., Du, C., Mohan, S., Yu, N., Modrusan, Z., Seshagiri, S. & 9 others, Yu, S. F., Pandita, A., Koeppen, H., French, D., Polson, A. G., Offringa, R., Whiting, N., Ebens, A. & Dornan, D., Mar 16 2011, In : Science Translational Medicine. 3, 74, 74ra22.

Research output: Contribution to journalArticle

27 Scopus citations

CD70+ non-Hodgkin lymphoma B cells induce Foxp3 expression and regulatory function in intratumoral CD4+CD25- T cells

Yang, Z. Z., Novak, A. J., Ziesmer, S. C., Witzig, T. E. & Ansell, S. M., Oct 1 2007, In : Blood. 110, 7, p. 2537-2544 8 p.

Research output: Contribution to journalArticle

126 Scopus citations

CDDO-imidazolide mediated inhibition of malignant cell growth in Waldenström macroglobulinemia

Elsawa, S. F., Novak, A. J., Grote, D., Konopleva, M., Andreeff, M., Witzig, T. E. & Ansell, S. M., Dec 2008, In : Leukemia Research. 32, 12, p. 1895-1902 8 p.

Research output: Contribution to journalArticle

5 Scopus citations
22 Scopus citations
14 Scopus citations

Checkpoint Inhibitors for the Treatment of Hodgkin Lymphoma

Bennani, N., Thanarajasingam, G. & Ansell, S. M., Feb 17 2016, (Accepted/In press) In : Expert Review of Clinical Immunology. p. 1-7 7 p.

Research output: Contribution to journalArticle

2 Scopus citations

Chronological age is a multifactorial prognostic variable in patients with Non-Hodgkin's Lymphoma

Ansell, S. M., Falkson, G., Van Der Merwe, R. & Uys, A., 1992, In : Annals of Oncology. 3, 1, p. 45-50 6 p.

Research output: Contribution to journalArticle

25 Scopus citations

Clinical heterogeneity of diffuse large B cell lymphoma following failure of front-line immunochemotherapy

Farooq, U., Maurer, M. J., Thompson, C. A., Thanarajasingam, G., Inwards, D. J., Micallef, I., Macon, W., Syrbu, S., Lin, T., Lin, Y., Ansell, S. M., Nowakowski, G. S., Habermann, T. M., Cerhan, J. R. & Link, B. K., Oct 1 2017, In : British Journal of Haematology. 179, 1, p. 50-60 11 p.

Research output: Contribution to journalArticle

15 Scopus citations

Clinical outcome of patients with subcutaneous panniculitis-like T-cell lymphoma

Ghobrial, I. M., Weenig, R. H., Pittlekow, M. R., Qu, G., Kurtin, P. J., Ristow, K. & Ansell, S. M., May 2005, In : Leukemia and Lymphoma. 46, 5, p. 703-708 6 p.

Research output: Contribution to journalArticle

48 Scopus citations

Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy

Jurinovic, V., Kridel, R., Staiger, A. M., Szczepanowski, M., Horn, H., Dreyling, M. H., Rosenwald, A., Ott, G., Klapper, W., Zelenetz, A. D., Barr, P. M., Friedberg, J. W., Ansell, S. M., Sehn, L. H., Connors, J. M., Gascoyne, R. D., Hiddemann, W., Unterhalt, M., Weinstock, D. M. & Weigert, O., Aug 25 2016, In : Blood. 128, 8, p. 1112-1120 9 p.

Research output: Contribution to journalArticle

68 Scopus citations
18 Scopus citations

Coinhibition of the deubiquitinating enzymes, USP14 and UCHL5, with VLX1570 is lethal to ibrutinib- or bortezomib-resistant Waldenstrom macroglobulinemia tumor cells

Paulus, A., Akhtar, S., Caulfield, T., Samuel, K., Yousaf, H., Bashir, Y., Paulus, S. M., Tran, D., Hudec, R., Cogen, D., Jiang, J., Edenfield, B., Novak, A. J., Ansell, S. M., Witzig, T. E., Martin, P., Coleman, M., Roy, V., Ailawadhi, S., Chitta, K. & 2 others, Linder, S. & Chanan Khan, A. A., Nov 4 2016, In : Blood Cancer Journal. 6, 11, e492.

Research output: Contribution to journalArticle

18 Scopus citations

Comparison of error rates in single-arm versus randomized phase II cancer clinical trials

Tang, H., Foster, N. R., Grothey, A. F., Ansell, S. M., Goldberg, R. M. & Sargent, D. J., Apr 10 2010, In : Journal of Clinical Oncology. 28, 11, p. 1936-1941 6 p.

Research output: Contribution to journalArticle

60 Scopus citations

Comprehensive analysis of tumor microenvironment cytokines in Waldenstrom macroglobulinemia identifies CCL5 as a novel modulator of IL-6 activity

Elsawa, S. F., Novak, A. J., Ziesmer, S. C., Almada, L. L., Hodge, L. S., Grote, D. M., Witzig, T. E., Fernandez-Zapico, M. E. & Ansell, S. M., Nov 17 2011, In : Blood. 118, 20, p. 5540-5549 10 p.

Research output: Contribution to journalArticle

50 Scopus citations

Constitutive activation of STAT5A and STAT5B regulates IgM secretion in Waldenström's macroglobulinemia

Hodge, L. S., Ziesmer, S. C., Yang, Z. Z., Secreto, F. J., Novak, A. J. & Ansell, S. M., Feb 13 2014, In : Blood. 123, 7, p. 1055-1058 4 p.

Research output: Contribution to journalArticle

11 Scopus citations

Cost-Effectiveness Analysis of a Risk-Adapted Algorithm of Plerixafor Use for Autologous Peripheral Blood Stem Cell Mobilization

Micallef, I., Sinha, S., Gastineau, D. A., Wolf, R., Inwards, D. J., Gertz, M., Hayman, S. R., Hogan, W., Johnston, P. B., Lacy, M., Ansell, S. M., Buadi, F., Dingli, D. M., Dispenzieri, A., Litzow, M. R., Porrata, L. F., Winters, J. L. & Kumar, S. K., Jan 2013, In : Biology of Blood and Marrow Transplantation. 19, 1, p. 87-93 7 p.

Research output: Contribution to journalArticle

58 Scopus citations

CXCR5 polymorphisms in non-Hodgkin lymphoma risk and prognosis

Charbonneau, B., Wang, A. H., Maurer, M. J., Asmann, Y., Zent, C. S., Link, B. K., Ansell, S. M., Weiner, G. J., Ozsan, N., Feldman, A. L., Witzig, T. E., Cunningham, J. M., Dogan, A., Habermann, T. M., Slager, S. L., Novak, A. J. & Cerhan, J. R., Sep 2013, In : Cancer Immunology, Immunotherapy. 62, 9, p. 1475-1484 10 p.

Research output: Contribution to journalArticle

17 Scopus citations

Cytokine gene polymorphisms and progression-free survival in classical Hodgkin lymphoma by EBV status: Results from two independent cohorts

Ghesquières, H., Maurer, M. J., Casasnovas, O., Ansell, S. M., Larrabee, B. R., Lech-Maranda, E., Novak, A. J., Borrel, A. L., Slager, S. L., Brice, P., Allmer, C., Brion, A., Ziesmer, S. C., Morschhauser, F., Habermann, T. M., Gaillard, I., Link, B. K., Stamatoullas, A., Fermé, C., Dogan, A. & 4 others, Macon, W. R., Audouin, J., Cerhan, J. R. & Salles, G., Nov 2013, In : Cytokine. 64, 2, p. 523-531 9 p.

Research output: Contribution to journalArticle

15 Scopus citations

Cytokines in the microenvironment of Waldenström's macroglobulinemia

Elsawa, S. & Ansell, S. M., 2009, In : Clinical Lymphoma and Myeloma. 9, 1, p. 43-45 3 p.

Research output: Contribution to journalArticle

10 Scopus citations

Dacetuzumab plus rituximab, ifosfamide, carboplatin and etoposide as salvage therapy for patients with diffuse large B-cell lymphoma relapsing after rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone: A randomized, double-blind, placebo-controlled phase 2b trial

Fayad, L., Ansell, S. M., Advani, R., Coiffier, B., Stuart, R., Bartlett, N. L., Forero-Torres, A., Kuliczkowski, K., Belada, D., Ng, E. & Drachman, J. G., Sep 2 2015, In : Leukemia and Lymphoma. 56, 9, p. 2569-2578 10 p.

Research output: Contribution to journalArticle

13 Scopus citations
21 Scopus citations

Defining lymphoplasmacytic lymphoma: Does MYD88L265P define a pathologically distinct entity among patients with an IgM paraprotein and bone marrow-based low-grade b-cell lymphomas with plasmacytic differentiation?

Fang, H., Kapoor, P., Gonsalves, W., Frederick, L. A., Viswanatha, D., Howard, M. T., He, R., Morice, W. G., McPhail, E., Greipp, P. T., Ansell, S. M., Kyle, R. A., Gertz, M., Paludo, J., Abeykoon, J. & King, R., Jul 3 2018, In : American Journal of Clinical Pathology. 150, 2, p. 168-176 9 p.

Research output: Contribution to journalArticle

2 Scopus citations

Denileukin diftitox in combination with rituximab for previously untreated follicular B-cell non-Hodgkin's lymphoma

Ansell, S. M., Tang, H., Kurtin, P. J., Koenig, P. A., Nowakowski, G. S., Nikcevich, D. A., Nelson, G. D., Yang, Z., Grote, D. M., Ziesmer, S. C., Silberstein, P. T., Erlichman, C. & Witzig, T. E., May 2012, In : Leukemia. 26, 5, p. 1046-1052 7 p.

Research output: Contribution to journalArticle

13 Scopus citations

Design and validity of a clinic-based case-control study on the molecular epidemiology of lymphoma

Cerhan, J. R., Fredericksen, Z. S., Wang, A. H., Habermann, T. M., Kay, N. E., Macon, W. R., Cunningham, J. M., Shanafelt, T. D., Ansell, S. M., Call, T. G., Witzig, T. E., Slager, S. L. & Liebow, M., 2011, In : International Journal of Molecular Epidemiology and Genetics. 2, 2, p. 95-113 19 p.

Research output: Contribution to journalArticle

31 Scopus citations